Johnson & Johnson (JNJ) Shares Bought by CapWealth Advisors LLC

CapWealth Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 1.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 118,306 shares of the company’s stock after purchasing an additional 2,215 shares during the quarter. Johnson & Johnson comprises approximately 2.7% of CapWealth Advisors LLC’s investment portfolio, making the stock its 10th biggest holding. CapWealth Advisors LLC’s holdings in Johnson & Johnson were worth $16,346,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NS Partners Ltd lifted its position in Johnson & Johnson by 0.5% during the third quarter. NS Partners Ltd now owns 183,604 shares of the company’s stock valued at $25,369,000 after purchasing an additional 937 shares during the period. Dynamic Technology Lab Private Ltd lifted its position in Johnson & Johnson by 393.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 15,854 shares of the company’s stock valued at $2,190,000 after purchasing an additional 12,644 shares during the period. Lido Advisors LLC lifted its position in Johnson & Johnson by 16.3% during the third quarter. Lido Advisors LLC now owns 30,820 shares of the company’s stock valued at $4,258,000 after purchasing an additional 4,322 shares during the period. Port Capital LLC lifted its position in Johnson & Johnson by 6.2% during the third quarter. Port Capital LLC now owns 20,855 shares of the company’s stock valued at $2,882,000 after purchasing an additional 1,224 shares during the period. Finally, Verity Asset Management Inc. acquired a new position in Johnson & Johnson during the third quarter valued at $276,000. 66.16% of the stock is currently owned by institutional investors and hedge funds.

Get Johnson & Johnson alerts:

JNJ has been the subject of a number of research reports. Citigroup decreased their target price on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Tuesday, November 20th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Thursday, December 20th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $152.00 target price (down from $162.00) on shares of Johnson & Johnson in a research report on Monday, January 14th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $142.81.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 3,643 shares of the company’s stock in a transaction dated Thursday, December 13th. The shares were sold at an average price of $147.31, for a total value of $536,650.33. Following the completion of the transaction, the chief accounting officer now owns 13,641 shares in the company, valued at $2,009,455.71. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Charles Prince acquired 2,000 shares of the firm’s stock in a transaction on Friday, December 14th. The stock was purchased at an average price of $134.37 per share, with a total value of $268,740.00. Following the transaction, the director now owns 28,520 shares of the company’s stock, valued at approximately $3,832,232.40. The disclosure for this purchase can be found here. Corporate insiders own 0.22% of the company’s stock.

Shares of Johnson & Johnson stock opened at $139.18 on Wednesday. The stock has a market capitalization of $370.40 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 2.18 and a beta of 0.68. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. The business had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.74 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 8.57 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were given a $0.90 dividend. The ex-dividend date was Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 44.01%.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase program on Monday, December 17th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to buy up to 1.5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4217234/johnson-johnson-jnj-shares-bought-by-capwealth-advisors-llc.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Bollinger Bands

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).